615320login-checkJACC Publication Guides Use of CareDx’s HeartCare Transplant Rejection Surveillance in Clinical Practice |
JANUARY, 26, 2023
Guide Helps Transplant Centers Continue the Evolution from Endomyocardial Biopsies to Noninvasive Surveillance Using AlloMap GEP and AlloSure dd-cfDNA
BRISBANE, Calif.–(BUSINESS WIRE)– CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the Journal of the American College of Cardiology (JACC): Heart Failure has published a detailed guide1 to help clinicians transition from routine invasive endomyocardial biopsy (EMB) to a less invasive acute rejection monitoring protocol in clinical practice.
615320login-checkJACC Publication Guides Use of CareDx’s HeartCare Transplant Rejection Surveillance in Clinical Practice |